GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.

HanesBrands has disclosed the departure of its CEO who is set to step down by the end of 2025 or upon the naming of a ...

Crocs has delivered a solid performance for fiscal year 2024 (FY24) with consolidated revenues reaching $4.1bn from $3.96bn ...

Cellebrite DI (CLBT) reported its fourth-quarter and full-year 2024 earnings, revealing a revenue of $109 million for Q4, surpassing expectations with an EPS of $0.08 against a forecast of $0.06. The ...

Q4 sales & FY 2024 resultsSales & Ebita margin in line with revised guidance 2024; FCF conversion exceeding objective Positive North ...

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 PatientsSHIELD II Enrolled more than ...

Adjusted operating income for the quarter totaled US$334 million, or US$4.99 per diluted share, compared to US$316 million, or US$4.73 per diluted share, a year earlier. Excluding notable items ...

QIAGEN N.V.’s QGEN fourth-quarter 2024 adjusted earnings per share (EPS) were 61 cents, the same at the constant exchange rate (CER). The reported figure increased 11% from the 2023 comparable figure.

For 2025, you can deduct up to $2,500. The deduction starts phasing out for single filers if your Modified Adjusted Gross Income (MAGI) exceeds $75,000 and is completely unavailable at $90,000.

Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for ...